期刊
ANNALS OF ONCOLOGY
卷 25, 期 12, 页码 2304-2313出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdu480
关键词
liquid biopsy; circulating tumor cells; circulating tumor DNA; precision medicine
类别
资金
- Fonds de la recherche scientifique (FNRS)
- Breast Cancer Research Foundation (BCRF)
- MEDIC Foundation
- 'Les Amis de l'Institut Bordet'
- Australian National Breast Cancer Foundation
- Victorian Cancer Agency Early Career Fellowship
- National Breast Cancer Foundation [ECF-14-027] Funding Source: researchfish
Next-generation sequencing studies have provided further evidence to support the notion that cancer is a disease characterized by Darwinian evolution. Today, we often fail to capture this evolution and treatment decisions, even in the metastatic setting, are often based on analysis of primary tumor diagnosed years ago. Currently, this is considered a major reason for treatment failures in cancer care. Recent technological advances in the detection and characterization of circulating tumor cells and circulating tumor DNA might address this and allow for treatment tailoring based on real-time monitoring of tumor evolution. In this review, we summarize the most important recent findings in the field, focusing on challenges and opportunities in moving these tools forward in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据